Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19 - The Centre for Evidence-Based Medicine
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients | eLife
In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression | Molecular Systems Biology
Frontiers | Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
Frontiers | Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19
ACE Inhibitor Pathway, Pharmacodynamics
ACE2 as a potential therapeutic target for pandemic COVID-19 - RSC Advances (RSC Publishing)
What Is an Angiotensin Converting Enzyme Inhibitor? | Circulation
Allosteric Site of ACE-2 as a Drug Target for COVID-19 | ACS Pharmacology & Translational Science
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19 | Hypertension Research
Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension | Hypertension
SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications - ScienceDirect
A historical perspective on ACE2 in the COVID-19 era | Journal of Human Hypertension
Role of the ACE2/Angiotensin 1–7 Axis of the Renin–Angiotensin System in Heart Failure | Circulation Research
IJMS | Free Full-Text | ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review
Frontiers | DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 | Hypertension Research
Pathways: ACE Inhibitor Pathway | www.antibodies-online.com
Cureus | A Review of the Mechanism of Action of Drugs Used in Congestive Heart Failure in Pediatrics | Article
COVID-19 and ACE -inhibitors and angiotensin receptor blockers-: The need to differentiate between early infection and acute lung injury | Revista Colombiana de Cardiología
Human recombinant soluble ACE2 in severe COVID-19 - The Lancet Respiratory Medicine
Angiotensin and the Coronavirus | Science | AAAS
COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ‐ Is there any scientific evidence for controversy? - Aleksova - 2020 - Journal of Internal Medicine - Wiley Online Library
COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Cour | CIA
